• Loading metrics

Neglected Parasitic Infections and Poverty in the United States

  • Peter J. Hotez

    Affiliations: National School of Tropical Medicine at Baylor College of Medicine, Houston, Texas, United States of America, Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development, Houston, Texas, United States of America, James A. Baker III Institute for Public Policy at Rice University, Houston, Texas, United States of America, Department of Biology, Baylor University, Waco, Texas, United States of America

Neglected Parasitic Infections and Poverty in the United States

  • Peter J. Hotez

The neglected tropical diseases (NTDs) are a group of chronic and disabling infections that occur primarily in settings of extreme poverty and affect over 1,000,000,000 people globally [1]. A selected group of neglected parasitic infections, including some which overlap with the World Health Organization's new list of recognized NTDs [2], are also common in the United States, where they disproportionately affect the poor. The major neglected parasitic infections in the US include Chagas disease, cysticercosis, toxocariasis, toxoplasmosis, and trichomoniasis. These five parasitic infections are considered “neglected” based on their high prevalence, chronic and disabling features, and their strong links with poverty [1], [2]. In contrast, the major intestinal parasitic infections found in the US—cryptosporidiosis, cyclosporiasis, and giardiasis—are mostly acute diarrheal illnesses without significant links to poverty or neglected populations. This review highlights new information (mostly from the last five years) on the major neglected parasitic infections affecting impoverished Americans, with respect to their distribution and unique clinical presentations as well as their surprising links to cardiovascular, respiratory, and neuropsychiatric conditions ordinarily thought of as noncommunicable diseases. Key diagnostic and therapeutic challenges and urgent needs for active surveillance and prevention are also presented.

Determinants of Neglected Parasitic Infections in the US

NTDs have been shown to flourish in settings of warm climate and extreme poverty found in global subtropical regions similar to the southern US. Indeed, new information suggests that many of the world's NTDs occur predominantly among the extreme poor living in the group of 20 (G20) countries, mostly in in the subtropics, including Brazil, Indonesia, India, China, Saudi Arabia, and Mexico [3]. It is now recognized that several neglected parasitic infections are also widespread in the southern US [4]. This finding is consistent with new US census data indicating that 20 million Americans now live in “extreme poverty” [5], with 1.65 million households (with 3.55 million children) living on less than US$2 per day in a given month [6]—a standard benchmark for global poverty. Today, the states with the highest poverty rates are all in the southern part of the country (Table 1) [7], and the nation's poorest large metropolitan area (McAllen-Edinburg-Mission, Texas) and the eight most impoverished smaller metropolitan areas are located in this region [8]. While there are noncash safety-net programs, including food stamps and public health insurance, that blunt some of the hardship of those living in extreme poverty, there has still been a clear increase in the number of Americans living in poverty over the last 40 years [5]. The underlying basis for why poverty promotes neglected parasitic infections in the southern US is unknown, although factors such as poor housing and sanitation and environmental contamination are likely contributors [5], while so far the links to ethnicity appear to be mainly socioeconomic. Through their chronic and disabling effects on worker productivity, child development, and maternal health [9], it is plausible that neglected parasitic infections could also help perpetuate generational poverty among people of color in the US.

Initial efforts to assess the prevalence or incidence of the neglected parasitic infections were hampered by a dearth of available data on these conditions [5], [10]. In response, legislation known as the “Neglected Infections of Impoverished Americans Act” (HR 528) was drafted to raise awareness of these diseases among the general public and subsequently introduced as a bill in 2010 and 2011 [11]. While efforts have since stalled in the US Congress, over the last five years additional information about the neglected parasitic infections has accumulated so that it is possible to begin making more informed statements on their status with regards to prevalence, geographic distribution, and novel associations with illnesses that resemble noncommunicable diseases (Table 2) and on the initial steps required for prevention.

Neglected Helminthic Infections

Toxocariasis and cysticercosis are two of the most common parasitic worm infections. Toxocariasis occurs disproportionately in the southern US. Less is known about the distribution of cysticercosis, but it also tends to concentrate in southern and southwestern states with large Hispanic American populations [12].


Toxocariasis is a soil-transmitted helminth infection and zoonosis that results from accidental ingestion of Toxcara canis or T. cati eggs found in soil contaminated with dog or cat feces, respectively. The resulting larval migrations through the lungs, liver, and eyes continue for months or even years to produce several different inflammatory conditions that include visceral toxocariasis, ocular toxocariasis, and covert toxocariasis with elevated serum immunoglobulin E (IgE) and eosinophilia [13]. Toxocariasis is widespread and is likely our nation's most common helminthiasis [13]. Much of what we currently know about the prevalence and risk factors for toxocariasis are from data on over 20,000 serum samples collected from the Third National Health and Nutrition Examination Survey (NHANES III) and tested by the Centers for Disease Control and Prevention (CDC) for Toxocara antibodies [14]. The age-adjusted seroprevalence was highest among non-Hispanic blacks (21.2%) and associated with low education, poverty, elevated lead concentrations, dog ownership, and living in the South or Northeast areas of the country [14], [15]. Toxocariasis and toxoplasmosis coinfections were also noted to be common [16]. Based on these data and the number of at-risk African Americans living in poverty, one estimate suggested that up to 2.8 million African Americans may have Toxocara infections [4], but there is a need to refine those estimates through further research. Among the compelling reasons to collect additional information about toxocariasis are potential links between the covert form and important pulmonary and neurologic sequelae [13]. An expanded NHANES III analysis recently linked toxocariasis to significantly diminished lung function [17] and reduced cognitive function in children [18]. Still other new studies support a link to epilepsy [19] but with conflicting evidence on the association with bronchial asthma [20]. Ocular toxocariasis is associated with vision loss, especially among children living in the South [21]. Given the high rates of toxocariasis among people living in the southern US and its association with cognitive delays, epilepsy, vision loss, and reduced pulmonary function, there is an urgent need to conduct prospective studies to confirm these links as well as to evaluate potential therapies with albendazole and other anthelminthic drugs [22]. The extent to which other soil-transmitted helminth infections still occur in the US is not known. As recently as 1982, ascariasis, trichuriasis, hookworm infection, and strongyloidiasis were prevalent in impoverished areas of the southern US and Appalachia, but over the last 30 years, there have been few if any high-quality studies to assess whether these infections still occur in historically endemic areas [23].


Cysticercosis is a human infection with the larval form of the pork tapeworm, Taenia solium, which results from the accidental ingestion of eggs passed in feces from another person, typically a family member or household contact. The disease is widely distributed in Latin America as well as in Asian and African developing countries, where it is an important global cause of epilepsy and manifestations of hydrocephalus, but it has also emerged as a public health problem among Hispanic-Americans living in the US. One estimate suggests that tens of thousands of cases are present at any given time [4]. The clinical presentation of cysticercosis in Houston, Texas, is typical of that seen in other regions of the US, with neurologic manifestations (“neurocysticercosis”), especially seizures and headaches, the most common presenting signs [24]. In the patient population seen at one of Houston's two major public hospitals, more than half have parenchymal disease, which is usually a solitary cyst (often with a scolex) seen on neuroimaging [24]. However, a significant percentage of cases also show intraventricular (20%) or subarachnoid disease (12%) or calcifications (12%) [24]. In southern California, where neurocysticercosis also causes a significant health and economic burden, most of the cases require hospitalization (at which point they are most frequently diagnosed), and men were more likely to suffer from severe disease including hydrocephalus, which was more costly and required longer hospital stays [25]. The American Academy of Neurology recently issued evidence-based guidelines for the treatment of neurocysticercosis and currently recommends specific anthelminthic therapy with albendazole either with our without corticosteroids in order to decrease the number of active lesions on brain imaging studies or to reduce long-term seizure frequency [26]. Such guidelines focus on parenchymal neurocysticercosis, so additional guidelines may be required to address more complicated disease. Substance P was identified as a possible factor responsible for seizures in neurocysticercosis [27], a finding which could provide new avenues for therapy. Importantly, cysticercosis can also be acquired in the US, but the actual extent to which this occurs is unknown [25], [28]. Pilot surveillance systems in California have screened contacts of neurocysticercosis cases for tapeworm carriage, identifying a source in up to 21% of US-born cases [28]. Treatment of these tapeworm carriers can prevent disease in their contacts.

Neglected Protozoan Infections

Three major protozoan infections have been linked to poverty in the US.

Chagas disease

Chagas disease (American trypanosomiasis) is a chronic parasitic infection caused by Trypanosoma cruzi, transmitted by triatomine vectors (“kissing” bugs), and associated with severe cardiomyopathy and other life-threatening sequelae in approximately one-third of infected individuals [29]. The CDC estimates that 300,167 people live with T. cruzi infection in the US, including up to 45,000 with undiagnosed Chagasic cardiomyopathy [29], [30]. A new economic analysis projects the healthcare and other costs of Chagas disease in the US to be almost US$900 million annually, placing it on a similar footing with other better-known infections such as Lyme disease and methicillin-resistant Staphylococcus aureus infection [31]. An important gap in our knowledge of the burden of Chagas disease in the US is an accurate estimate of the number of infants being infected through mother-to-child transmission [32]. The first case of congenital Chagas disease was confirmed in 2012 [33], but it has been estimated that up to 315 infants annually (in the same order of magnitude as phenylketonuria or other inborn errors of metabolism) are born in the US with congenital Chagas disease [29]. Information on the number of infected infants and highest-risk groups could inform policies on targeted screening. Limited data suggest that up to 13% of patients with dilated cardiomyopathy in at-risk Latino populations in the US may be due to Chagas disease [34]. More accurate estimates of the burden, risk groups, and costs would inform treatment guidelines and prevent disease progression. Another major unknown is the proportion of cases in the US due to immigration from endemic areas of Latin America versus those attributable to autochthonous transmission. The triatomine vectors are widely distributed in the southern US [30], especially in Texas, where canine Chagas disease is also widespread [35]. However, to date only 23 cases of autochthonous Chagas disease have been confirmed [36]. Reasons for the lack of clarity on disease burden include limited public health surveillance and targeted surveys and poor disease-related knowledge among American physicians [37]. Few obstetricians know about the risk of congenital Chagas disease [38]. Finally, the diagnostic tests for Chagas are not easily accessible, and the antitrypanosomal drugs are highly toxic, often of limited efficacy, and contraindicated in pregnancy [30].


Toxoplasmosis is a parasitic infection of humans and numerous animal species. Transmission of Toxoplasma gondii to humans occurs through either ingestion of cysts found in meat or oocysts found in water or soil contaminated by cat feces [39]. Based on NHANES 1999–2004 and the 2009 US census data, almost 1.1 million people are infected each year, including more than 21,505 people who develop ocular lesions [40]. While overall the prevalence of toxoplasmosis has declined from the prior decade, the disease still occurs disproportionately among non-Hispanic blacks and people living in poverty [39]. Up to 4,000 cases of congenital toxoplasmosis also occur annually [41]. Interestingly, a new test that detects antibodies to sporozoites has recently suggested that most congenital infections result from ingestion of T. gondii oocysts (zoonotically transmitted from cats) during pregnancy [42]. There are also data to indicate that severe disease resulting from congenital toxoplasmosis is more common in the US than in Europe [43]. However, despite this new information, there is a low level of awareness among obstetricians about toxoplasmosis and how to prevent infection [44]. The burden of T. gondii infection may extend beyond well-known manifestations that include ocular disease, congenital defects, and severe disease in the immunocompromised host. Some recent studies have also indicated an association between seropositivity and various psychiatric conditions, including schizophrenia, bipolar and other mood disorders, and suicide attempts [45][47]. Addressing important gaps in our understanding of this disease, such as estimates of incidence of congenital toxoplasmosis and cost/benefit of screening; elucidation of the association between T. gondii infection and mental illness; and improved diagnostic tests and treatments, would enable better prevention and control in the US.


Trichomoniasis is a common sexually transmitted parasitic infection with more than 7 million cases annually in the US, where it is a leading cause of vaginitis, preterm labor, and pelvic inflammatory disease [48]. Data collected over the last decade has also revealed an important link with HIV/AIDS, as women with Trichomonas vaginalis infection exhibit increased HIV viral shedding, which has been shown to decrease following antiparasitic chemotherapy [49]. Indeed, a significant number of HIV transmission events from HIV-infected women may be attributable to trichomoniasis coinfections [50]. The prevalence of trichomoniasis is more than ten times higher among black women than non-Hispanic white women [51]. Other factors associated with Trichomonas infection in this national sample included poverty, low educational level, increasing age, high number of sex partners, being born in the US, douching, and having a concurrent chlamydial infection [51]. Nitroimidazoles (metronidazole or tinidizole) are the only class of drug available in the US for treatment. Low levels of metronidazole resistance are now widespread among T. vaginalis isolates in US urban centers [52]. The CDC has also received isolates that have been resistant to tinidazole. In addition, some women are allergic to the nitroimidazoles and require desensitization, so other drugs are urgently needed. Addressing important gaps in the epidemiology of this disease, including the role of asymptomatic infections in disease transmission and the role of male infections, is needed to inform prevention policies.

Other protozoan infections

Two other intestinal protozoan infections, i.e., cryptosporidiosis and giardiasis, are also common in the US, where they are neither linked to neglect nor poverty. Both diseases were reviewed recently with respect to their epidemiology in the US [53], [54]. Briefly, both infections are more prevalent in the northern US and exhibit their highest incidence during the summer months with links to recreational water use [53], [54]. Cyclosporiasis is a parasitic infection linked to food-borne illness, also with high incidence during the summer months [55].

Urgent Needs and Future Directions

The neglected parasitic infections are not rare conditions in the US. Instead, they affect at least 12 million Americans, either through new infections (e.g., trichomoniasis) or from prevalent persistent infections resulting in chronic sequelae. However, these diseases typically go undiagnosed because of poor awareness among health care providers as well as the relative inaccessibility or unavailability of the diagnostic tests. Confirmatory diagnostic testing for these parasitic infections requires serologic testing that detects antibody against antigens obtained from whole parasites that are typically unavailable in most clinical laboratories. Therefore, there is an urgent need to develop improved diagnostic reagents (including recombinant antigens) and point-of-care tests. The chronic and disabling features of neglected parasitic infections can resemble selected noncommunicable diseases, which further compounds diagnostic difficulties and their lack of recognition. As examples, few health care providers might recognize toxocariasis and toxoplasmosis as underlying causes of pediatric cognitive deficits and developmental delays, toxocariasis as a cause of asthma, toxocariasis and cysticercosis as etiologies of epilepsy, or Chagas disease as a cause of heart disease. In addition to the lack of diagnostic tools, better drugs are urgently needed to either overcome resistance or have a better safety profile. There is no Food and Drug Administration (FDA)-approved drug for Chagas disease in the US, which limits the ability to scale up a treatment program for thousands of people in the US. The drugs, however, are available under investigational protocols from the CDC. Almost all of our current estimates of disease prevalence, incidence, or disease burden are based on limited testing or NHANES surveys. While blood products are screened for T. cruzi antibody [36], [56], such activities underestimate the true prevalence and geographic distribution of an infection like Chagas disease that occurs mostly among the poor [30]. For some diseases like Chagas disease or neurocysticercosis, for which there is a potential public health response such as screening children of infected mothers or screening household contacts of neurocysticercosis for taeniasis, public health surveillance is appropriate but seldom conducted except in a few states. Currently, Chagas disease is reportable in only four states and neurocysticercosis in five states, but even in these states there are few if any programs of active surveillance. Such limited surveillance activities hinder efforts to assess disease burdens, identify at-risk populations, and elucidate modes of transmissions. Finally, we need programs of health education and advocacy to promote awareness for the neglected parasitic infections and to shape policies for control and prevention. Pediatricians and obstetricians in particular can play a major role in advising families how to prevent these diseases. Communities need to enact and enforce regulations that prohibit pet access to children's play areas in public parks and programs to prevent T. canis, T. cati, and T. gondii zoonotic transmission from dog and cat feces. Directing attention and resources to the neglected parasitic infections would provide a cornerstone for a broader approach to help the most impoverished and marginalized Americans.


PJH wishes to thank Capt. Monica E. Parise, MD, and Dana Woodhall, MD, from the Parasitic Disease Branch of the CDC for their input and advice on the manuscript.


  1. 1. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, et al. (2007) Control of neglected tropical diseases. N Engl J Med 357: 1018–1027. doi: 10.1056/nejmra064142
  2. 2. World Health Organization (2010) Working to overcome the global impact of neglected tropical diseases: First WHO report on neglected tropical diseases. Geneva: World Health Organization. Available: Accessed 2 August 2013.
  3. 3. Hotez PJ (2013) NTDs V.2.0: “Blue Marble Health”—Neglected Tropical Disease Control and Elimination in a Shifting Health Policy Landscape. PLoS Negl Trop Dis 7: e2570. doi: 10.1371/journal.pntd.0002570
  4. 4. Hotez PJ (2008) Neglected infections of poverty in the United States of America. PLoS Negl Trop Dis 2: e256. doi: 10.1371/journal.pntd.0000256
  5. 5. Denavas-Walt C, Proctor BD, Smith JC, US Census Bureau (2011) Income, Poverty, and Health Insurance Coverage in the United States: 2010. Available: Accessed 25 August 2012.
  6. 6. Shaefer HL, Edin K (2013) Rising extreme poverty in the United States and the response of federal means-tested transfer programs. National Poverty Center Working Paper Series #13-06, May 2013. Available: Accessed 28 March 2014.
  7. 7. US Census Bureau (2012) Poverty: Income, Poverty and Health Insurance in the United States: 2011—Tables & Figures. Available: Accessed 6 April 2013.
  8. 8. Gabe T (2013) Poverty in the United States: 2012. Congressional Research Service, Report for Congress, November 13, 2013. Available: Accessed 6 April 2013.
  9. 9. Hotez PJ, Fenwick A, Savioli L, Molyneux DH (2009) Rescuing the bottom billion through control of neglected tropical diseases. Lancet 373: 1570–1575. doi: 10.1016/s0140-6736(09)60233-6
  10. 10. Hotez P, Stillwaggon E, McDonald M, Todman L, DiGrazia L (2010) National summit on neglected infections of poverty in the United States. Emerg Infect Dis 16: e1. doi: 10.3201/eid1605.091863
  11. 11. Sunlight Foundation, OpenCongress (2011) H.R. 528 – Neglected Infections of Impoverished Americans Act of 2011. Available: Accessed 6 April 2013.
  12. 12. Pew Research Center (2014) Hispanic Trends Project. Statistical Portrait of the Hispanic Population in the United States, 2001. Hispanic Population, by State: 2011. Available: Accessed 2 August 2013.
  13. 13. Hotez PJ, Wilkins PP (2009) Toxocariasis: America's most common neglected infection of poverty and a helminthiasis of global importance. PLoS Negl Trop Dis 3: e400. doi: 10.1371/journal.pntd.0000400
  14. 14. Won KY, Kruszon-Moran D, Schantz PM, Jones JL (2008) National seroprevalence and risk factors for zoonotic Toxocara spp. Infection. Am J Trop Med Hyg 79: 552–557.
  15. 15. Congdon P, Lloyd P (2011) Toxocara infection in the United States: the relevance of poverty, geography and demography as risk factors, and implications for estimating county prevalence. Int J Publ Health 56: 15–24. doi: 10.1007/s00038-010-0143-6
  16. 16. Jones JL, Kruszon-Moran D, Won K, Wilson M, Schantz PM (2008) Toxoplasma gondii and Toxocara spp. Co-infection. Am J Trop Med Hyg 78: 35–39.
  17. 17. Walsh MG (2011) Toxocara infections and diminished lung function in a nationally representative sample from the United States population. Int J Parasitol 41: 243–247. doi: 10.1016/j.ijpara.2010.09.006
  18. 18. Walsh MG, Haseeb MA (2012) Reduced cognitive function in children with toxocariasis in a nationally representative sample of the United States. Int J Parasitol 42: 1159–1163. doi: 10.1016/j.ijpara.2012.10.002
  19. 19. Quattrocchi G, Nicoletti A, Marin B, Bruno E, Druet-Cabanac M, Preux P-M (2012) Toxocariasis and epilepsy: systematic review and meta-analysis. PLoS Negl Trop Dis 6: e1775. doi: 10.1371/journal.pntd.0001775
  20. 20. Pinelli E, Aranzamendi C (2012) Toxocara infection and its association with allergic manifestations. Endocrin Metabol Immun Disorders Drug Targets 12: 33–44. doi: 10.2174/187153012799278956
  21. 21. Woodhall D, Starr MC, Montgomery SP, Jones JL, Lum F, et al. (2012) Ocular toxocariasis: epidemiologic, anatomic, and therapeutic variations based on a survey of ophthalmic subspecialists. Ophthalmology 119: 1211–1217. doi: 10.1016/j.ophtha.2011.12.013
  22. 22. Othman AA (2012) Therapeutic battle against larval toxocariasis: are we still far behind? Acta Trop 124: 171–178. doi: 10.1016/j.actatropica.2012.08.003
  23. 23. Starr MC, Montgomery SP (2011) Soil-transmitted helminthiases in the United States: a systematic review – 1940–2010. Am J Trop Med Hyg 85: 680–684. doi: 10.4269/ajtmh.2011.11-0214
  24. 24. Serpa JA, Graviss EA, Kass JS, White AC Jr (2011) Neurocysticercosis in Houston, Texas. Medicine 90: 81–86. doi: 10.1097/md.0b013e318206d13e
  25. 25. Croker C, Redelings M, Reporter R, Sorvillo F, Mascola L, et al. (2012) The impact of neurocysticercosis in California: a review of hospitalized cases. PLoS Negl Trop Dis 6: e1480. doi: 10.1371/journal.pntd.0001480
  26. 26. Baird RA, Wiebe S, Zunt JR, Halperin JJ, Gonseth G, et al. (2013) Evidence-based guideline: treatment of parenchymal neurocysticercosis. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 80: 1424–1429. doi: 10.1212/wnl.0b013e31828c2f3e
  27. 27. Robinson P, Garza A, Weinstock J, Serpa JA, Goodman JC, et al. (2012) Substance P causes seizures in neurocysticercosis. PLoS Pathog 8: e1002489. doi: 10.1371/journal.ppat.1002489
  28. 28. Sorvillo F, Wilkins P, Shafir S, Eberhard M (2011) Public health implications of cysticercosis acquired in the United States. Emerg Infect Dis 17: 1–6. doi: 10.3201/eid1701.101210
  29. 29. Bern C, Montgomery SP (2009) An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 49: e52–e54. doi: 10.1086/605091
  30. 30. Bern C, Kjos S, Yabsley MJ, Montgomery SP (2011) Trypanosoma cruzi and Chagas' disease in the United States. Clin Microbiol Rev 24: 655–681. doi: 10.1128/cmr.00005-11
  31. 31. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ (2013) Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis 13: 342–348. doi: 10.1016/s1473-3099(13)70002-1
  32. 32. Buekens P, Almendares O, Carlier Y, Dumonteil E, Eberhard M, et al. (2008) Mother-to-child transmission of Chagas disease in North America: why don't we do more? Matern Child Health J 12: 283–286. doi: 10.1007/s10995-007-0246-8
  33. 33. Centers for Disease Control and Prevention (2012) Congenital transmission of Chagas disease – Virginia, 2010. MMWR Morb Mortal Wkly Rep 61: 477–479.
  34. 34. Kapelusznik L, Varela D, Montgomery SP, Shah AN, Steurer FJ, et al. (2013) Chagas disease in Latin American immigrants with dilated cardiomyopathy in New York City. Clin Infect Dis 57: e7. doi: 10.1093/cid/cit199
  35. 35. Sarkar S, Strutz SE, Frank DM, Rivaldi C-L, Sissel B, et al. (2010) Chagas disease risk in Texas. PLoS Negl Trop Dis 4: e836. doi: 10.1371/journal.pntd.0000836
  36. 36. Cantey PT, Stramer SL, Townsend RL, Kamel H, Ofafa K, et al. (2012) The United Trypanosoma cruzi infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion 52: 1922–1930. doi: 10.1111/j.1537-2995.2012.03581.x
  37. 37. Stimpert KK, Montgomery SP (2010) Physician awareness of Chagas disease, USA. Emerg Infect Dis 16: 871–872. doi: 10.3201/eid1605.091440
  38. 38. Verani JR, Montgomery SP, Schulkin J, Anderson B, Jones JL (2010) Survey of obstetrician-gynecologists in the United States about Chagas disease. Am J Trop Med Hyg 83: 891–895. doi: 10.4269/ajtmh.2010.09-0543
  39. 39. Jones JL, Kruszon-Moran D, Sanders-Lewis K, Wilson M (2007) Toxoplasma gondii infection in the United States, 1999–2004, decline from the prior decade. Am J Trop Med Hyg 77: 405–410.
  40. 40. Jones JL, Holland GN (2010) Short report: annual burden of ocular toxoplasmosis in the United States. Am J trop Med Hyg 82: 464–465. doi: 10.4269/ajtmh.2010.09-0664
  41. 41. Lopez A, Dietz V, Wilson M, Navin TR, Jones JL (2000) Preventing congenital toxoplasmosis. MMWR Recomm Rep 49: 37–75.
  42. 42. Boyer K, Hill D, Mui E, Wroblewski K, Karrison T, Dubey JP, et al. (2011) Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin Infect Dis 53: 1081–1089. doi: 10.1093/cid/cir667
  43. 43. Olariu TR, Remington JS, McLeod R, Alam A, Montoya JG (2011) Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants. Pediatr Infect Dis J 30: 1056–1061. doi: 10.1097/inf.0b013e3182343096
  44. 44. Jones JL, Krueger A, Schulkin J, Schantz PM (2010) Toxoplasmosis in prevention and testing in pregnancy, survey of obstetrician-gynaecologists. Zoonoses Publ Health 57: 27–33. doi: 10.1111/j.1863-2378.2009.01277.x
  45. 45. Torrey EF, Bartko JJ, Yolken RH (2012) Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr Bull 38: 642–647. doi: 10.1093/schbul/sbs043
  46. 46. Arling TA, Yolken RH, Lapidus M, Langenberg P, Dickerson FB, et al. (2009) Toxoplasma gondii antibody titers and history of suicide attempts in patients with recurrent mood disorders. J Nerv Ment Dis 197: 905–908. doi: 10.1097/nmd.0b013e3181c29a23
  47. 47. Hamdani N, Daban-Huard C, Lajnef M, Richard JR, Delavest M, et al. (2013) Relationship between Toxoplasma gondii infectiona nd bipolar disorder in a French sample. J Affect Disord 148: 444–448. doi: 10.1016/j.jad.2012.11.034
  48. 48. Coleman JS, Gaydos CA, Witter F (2013) Trichomonas vaginalis vaginitis in obstetrics and gynecology practice: new concepts and controversies. Obstet Gynecol Surv 68: 43–50. doi: 10.1097/ogx.0b013e318279fb7d
  49. 49. Kissinger P, Amedee A, Clark RA, Dumestre J, Theall KP, et al. (2009) Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis 36: 11–16. doi: 10.1097/olq.0b013e318186decf
  50. 50. Quinlivan EB, Patel SN, Grodensky CA, Golin CE, Tien HC, et al. (2012) Modeling the impact of Trichomonas vaginalis infection on HIV transmission in HIV-infected individuals in medical care. Sex Transm Dis 39: 671–677. doi: 10.1097/olq.0b013e3182593839
  51. 51. Sutton M, Sternberg M, Koumans EH, McQuillan G, Berman S, et al. (2007) The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001–2004. Clin Infect Dis 45: 1319–1326. doi: 10.1086/522532
  52. 52. Kirkcaldy RD, Augostini P, Asbel LE, Bernstein KT, Kerani RP, et al. (2012) Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009–2010. Emerg Infect Dis 18: 939–943. doi: 10.3201/eid1806.111590
  53. 53. Yoder JS, Wallace RM, Collier SA, Beach MJ, Hlavasa MC (2012) Cryptosporidiosis surveillance – United States, 2009–2010. MMWR Surveill Summ 61: 1–12.
  54. 54. Yoder JS, Gargano JW, Wallace RM, Beach MJ (2012) Giardiasis surveillance - United States, 2009–2010. MMWR Surveill Summ 61: 13–23.
  55. 55. Hall RL, Jones JL, Hurd S, Smith G, Mahon BE, et al. (2012) Population-based active surveillance for Cyclospora infection – United States, Foodborne Diseases Active Surveillance Network (FoodNet), 1997–2009. Clin Infect Dis 54 Suppl 5: S411–S417. doi: 10.1093/cid/cis049
  56. 56. Kessler DA, Shi PA, Avecilla ST, Shaz BH (2013) Results of lookback for Chagas disease since the inception of donor screening at New York Blood Center. Transfusion 53: 1083–1087. doi: 10.1111/j.1537-2995.2012.03856.x